Needham Keeps Their Hold Rating on TransMedics Group (TMDX)

In a report released today, Michael Matson from Needham maintained a Hold rating on TransMedics Group (TMDX – Research Report). The company’s shares closed yesterday at $141.96.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

According to TipRanks, Matson is an analyst with an average return of -7.0% and a 37.35% success rate. Matson covers the Healthcare sector, focusing on stocks such as TransMedics Group, Merit Medical Systems, and Establishment Labs Holdings.

TransMedics Group has an analyst consensus of Moderate Buy, with a price target consensus of $124.00.

The company has a one-year high of $177.37 and a one-year low of $55.00. Currently, TransMedics Group has an average volume of 1.04M.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year. Earlier this month, Anil P. Ranganath, the SVP, GC and Secretary of TMDX sold 686.00 shares for a total of $95,902.80.